Tuesday, Argenx SE (NASDAQ: ARGX) released topline results from the ADVANCE-SC study evaluating Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with primary immune thrombocytopenia (ITP), an autoimmune disorder defined by a significantly reduced number
The FDA issued a complete response letter to Aldeyra Therapeutics Inc's (NASDAQ: ALDX) New Drug Application (NDA) of reproxalap, an investigational drug
Novartis AG (NYSE: NVS) has outlined the progress made in delivering its pure-play strategy, focused on four core therapeutic areas (Cardiovascular-Renal-Metabolic, Immunology, Neuroscience, Oncology), two plus three technology platforms (Chemistry, Biotherapeutics, xRNA, Radioligand, Gene & Cell Therapy) in four priority geographies (US, China, Germany, Japan).
The S&P CoreLogic Case-Shiller U.S. National Home Price NSA Index, covering all nine U.S. census divisions, reported a 3.9% annual change in September, up from a 2.5% change in the previous month.
Avidity Biosciences Inc (NASDAQ: RNA) announced a global licensing and research collaboration with Bristol Myers Squibb & Co (NYSE: BMY) focused on discovering, developing, and commercializing multiple ca
The FDA approved SpringWorks Therapeutics Inc's (NASDAQ: SWTX) Ogsiveo (nirogacestat), an oral gamma-secretase inhibitor, for adult patients with progressing desmoid tumors who